BONEMATE RESEARCH

Back to Osteoporosis

Kovacs A. "Efficacy of Ipriflavone in the Prevention and Treatment of Post-menopausal Osteoprosis." Agents Actions (1994): 41:86-87.

"The efficacy of Ipriflavone was investigated in a one-year, double-blind, placebo-controlled parallel group clinical trial. After six months, the bone mineral density of the vertebral region increased in the Ipriflavone treated group, whereas it decreased in the placebo-treated group. The differences between the treatment groups were statistically significant."

Adami D, Bufalino L. Cervetti R, DiMarco c, DiMunno O, Fantasia L, Isaia C, Passeri M, Serni U, Vecchiet L. "Ipriflavone Prevents Radical Bone Loss in Post-menopausal Women with Low Bone Mass Over Two Years." Osteoporosis Int 7 (1997)L 2): 119-125.

"Two hundred fifty-five post menopausal women with distal forearm bone mineral density (BMD) 1 SD below the mean value were randomly allocated to a two year administration of Ipriflavone (200mg t.i.d.) or matched placebo. The between treatment difference is significant at year 1 and year 2."

Passeri M, Biodo M, Costi D, Bufalino L, Caastiglione GN, DiPeppe C, Abate G. "Effect of Ipriflavone on Bone Mass in Elderly Osteoporotic Women." Bone and Mineral (1992): 9(supple): S57-S62.

"Twenty-six post-menopausal osteoporotic women were studied with one-year treatment of Ipriflavone. The results of this study showed that a 12 month treatment with Ipriflavone induces a significant increase in bone density at the distal radius in osteoporatic women."

Agnusdei D, Adami S, et al. "Effects of Ipriflavone on Bone Mass and Calcium Metabolism in Post-menopausal Osteoporosis." Bone and Mineral (1992): 9(supple): S43-S48.

"A 2-year multicenter, double-blind, placebo-controlled clinical study was performed to evaluate the efficacy of Ipriflavone. The study concluded that Ipriflavone has significant efficacy on bone mass and the good safety and tolerability profile indicate the agent has potentiality on post menopausal osteoporosis."

Agnusdei D, Zacchei F, Bigazzi S, Cepollaro C, Nardi P, Montagnani M, Gennari C. "Metabolic Effects of Ipriflavone in Established Post-menopausal Osteoporosis." Drug Experimental Clinical Research (1989): XV(2):97-104.

"A six-month, double-blind, placebo-controlled, post-menopausal osteoporosis study was performed to evaluate the bone density enhancing ability of Ipriflavone. The parameters investigated showed a significant reduction of osteocalcin in the Ipriflavone group that indicates a modulation of bone turnover."

Johansson C, Black D, Johnell O, Mellstrom D. "Bone Mineral Density Is a Predictor of Survival." Calcified Tissue International (1998): 63:190-196.

"Bone mineral density is a stronger predictor of subsequent mortality in both women and men. The relationship between bone mineral density is as strong or stronger than that between other established predictors of mortality such as cholesterol and blood pressure."

Passeri M, et al. "Effects of 2-year Therapy with Ipriflavone in Elderly Women with Established Osteoporosis." Int J Mineral Electrolyte Metab (1995): 9:137-144.

"A double-blind, placebo-controlled study conducted for two years with elderly women consuming 600 mg daily Ipriflavone with one gram calcium compared to women with 1 gram of calcium alone. The fracture rate is significantly reduced in the Ipriflavone group."

Agnusdei D, Bufalino L, Crepaldi G, Gennari C, Isaia C, Mazzuoli G, Ortolani S, Passeri M. "A Double-Blind, Placebo-Controlled Trial of Ipriflavone for Prevention of Post-menopausal Spinal Bone Loss." Calcified Tissue International (1997):61(2):142-147.

"The difference between the treatment group and placebo group was significant. Urine Hydroxyproline/creatinine showed a significant decrease only in the Ipriflavone treated group suggesting an inhibitory effect on bone turnover rate."

Agnusdei D, Bufalino L. "Efficacy of Ipriflavone in Established Osteoporosis and Long Term Safety." Calcified Tissue International (1997) 61:S23-S27.

"Ipriflavone was shown to positively affect bone mineralization and to be endowed with a fair safety profile, thus supporting a favorable risk/benefit ratio."

Civitelli R. "In Vitro and In Vivo Effect of Ipriflavone on Bone Formation and Bone Biomechanics." Clacified Tissue International (1997): 61:S12-S14.

"Using in vitro and in vivo models, Ipriflavone was shown that it may stimulate bone formation in addition to antiresorptive activity. A one month treatment with Ipriflavone showed increased bone density and improved the biomechanical properties of adult male rate bones without altering mineral composition or bone crystallinity."

Gennari C, Adami D, Bufalino L, Crepaldi G, DiMarco C, DiMunno O, Fantasia L, Isaia C, Mazzuoli GF, Ortolini S, Passeri M, Serni U, Vecchiet L. "Effect of Chronic Treatment With Ipriflavone in Postmenopausal Women With Low Bone Mass." Calcified Tissue International (1997): 61:S19-S22.

"Between February 1990 and December 1991, 453 post menopausal women were enrolled in 13 centers specializing in osteoporosis care. The results of this multicenter, double-blind, placebo controlled, 2-year studies to evaluate the efficacy and tolerability of Ipriflavone in post-menopausal women with low bone mass are significant. The final outcome was a bone sparing effect of 1.6% and 3.5% respectively in these two studies."

Valente M, Bufalino L, Castiglione GN, D'Angelo R, Mancuso A, Galoppi P, Zichella L. "Effects of 1-Year Treatment with Ipriflavone on Bone in Post-menopausal Women with Low Bone Mass." Calcified Tissue International (1994): 54:377-380.

"Forty post-menopausal women with low bone mineral density were enrolled and randomly treated for 12 months with Ipriflavone 600 mg/day or placebo. At the end of 6 months, a reduction of bone mineral density was evidenced in the placebo group and an increase of bone mineral density was obtained in the Ipriflavone group."